NASDAQ:ABUS Arbutus Biopharma (ABUS) Stock Price, News & Analysis $3.90 -0.02 (-0.51%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.86▼$3.9850-Day Range$2.95▼$3.9252-Week Range$1.69▼$3.98Volume729,701 shsAverage Volume1.13 million shsMarket Capitalization$736.01 millionP/E RatioN/ADividend YieldN/APrice Target$4.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Arbutus Biopharma alerts: Email Address Arbutus Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside11.1% Upside$4.33 Price TargetShort InterestBearish3.72% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector873rd out of 936 stocksPharmaceutical Preparations Industry409th out of 436 stocks 2.5 Analyst's Opinion Consensus RatingArbutus Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArbutus Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Arbutus Biopharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.72% of the outstanding shares of Arbutus Biopharma have been sold short.Short Interest Ratio / Days to CoverArbutus Biopharma has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Arbutus Biopharma has recently increased by 16.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArbutus Biopharma does not currently pay a dividend.Dividend GrowthArbutus Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABUS. Previous Next 2.5 News and Social Media Coverage News SentimentArbutus Biopharma has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Arbutus Biopharma this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for ABUS on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows6 people have added Arbutus Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arbutus Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Arbutus Biopharma is held by insiders.Percentage Held by Institutions43.79% of the stock of Arbutus Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arbutus Biopharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arbutus Biopharma are expected to decrease in the coming year, from ($0.39) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arbutus Biopharma is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arbutus Biopharma is -8.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArbutus Biopharma has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arbutus Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyNvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.To see Porter Stansberry's new AI prediction go here now. About Arbutus Biopharma Stock (NASDAQ:ABUS)Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Read More ABUS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABUS Stock News HeadlinesJuly 25 at 4:14 AM | americanbankingnews.comArbutus Biopharma (ABUS) Scheduled to Post Earnings on ThursdayJuly 20, 2024 | msn.comArbutus Biopharma to Reveal Q2 Financials and Corporate UpdatesJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.July 18, 2024 | globenewswire.comArbutus to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateJuly 5, 2024 | seekingalpha.comArbutus Biopharma: Focused On HBV With A Potentially Huge Litigation 'Wildcard'July 5, 2024 | seekingalpha.comArbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy OpportunityJune 6, 2024 | globenewswire.comTreatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsJune 5, 2024 | globenewswire.comArbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureJuly 27, 2024 | Porter & Company (Ad)Nvidia insiders dumping sharesAll the signs show the AI market is about to reverse. And unless you know what’s really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too. Click here to read the new expose, The Big AI Die-Up while you still can.June 3, 2024 | globenewswire.comArbutus Distributors Ltd. News ReleaseMay 29, 2024 | globenewswire.comArbutus to Participate in Jefferies Global Healthcare ConferenceMay 22, 2024 | globenewswire.comArbutus to Present Imdusiran Data at EASL Congress 2024May 17, 2024 | morningstar.comArbutus Biopharma Corp ABUSMay 17, 2024 | bizjournals.comMike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus BiopharmaMay 17, 2024 | finance.yahoo.comArbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | finance.yahoo.comUpdate: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | businesswire.comWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueMay 10, 2024 | msn.comArbutus Biopharma to Engage Investors at Upcoming New York ConferencesSee More Headlines Receive ABUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABUS CUSIPN/A CIK1447028 Webwww.arbutusbio.com Phone(267) 469-0914Fax604-419-3201Employees90Year Founded1992Price Target and Rating Average Stock Price Target$4.33 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+11.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-72,850,000.00 Net Margins-572.81% Pretax Margin-572.81% Return on Equity-62.68% Return on Assets-47.22% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$18.14 million Price / Sales40.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book6.19Miscellaneous Outstanding Shares188,720,000Free Float181,168,000Market Cap$736.01 million OptionableOptionable Beta1.96 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Michael J. McElhaugh (Age 49)Co-Founder, Interim President, CEO & Director Comp: $606.62kDr. Michael J. Sofia Ph.D. (Age 66)Chief Scientific Officer Comp: $628.43kMr. David C. Hastings CPA (Age 63)CFO & Chief Accounting Officer Comp: $647.1kMs. Lisa M. CaperelliVice President of Investor RelationsMr. J. Christopher Naftzger BA (Age 57)Esq., J.D., General Counsel, Chief Compliance Officer & Secretary Ms. Shannon Briscoe SPHRVice President of Human ResourcesDr. Karen Sims M.D. (Age 53)Ph.D., Chief Medical Officer Mr. R. Hector Mackay-Dunn B.A. (Age 73)J.D., L.L.B., Q.C., Corporate Secretary More ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVAltimmuneNASDAQ:ALTKamadaNASDAQ:KMDAF-star TherapeuticsNASDAQ:FSTXBeyondSpringNASDAQ:BYSIView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 86,104 shares on 7/26/2024Ownership: 0.262%Premier Path Wealth Partners LLCBought 5,500 shares on 7/24/2024Ownership: 0.019%Clear Harbor Asset Management LLCSold 15,500 shares on 7/17/2024Ownership: 0.053%Tidal Investments LLCBought 43,155 shares on 5/17/2024Ownership: 0.023%Walleye Trading LLCBought 14,000 shares on 5/17/2024Ownership: 0.007%View All Institutional Transactions ABUS Stock Analysis - Frequently Asked Questions How have ABUS shares performed this year? Arbutus Biopharma's stock was trading at $2.50 at the start of the year. Since then, ABUS stock has increased by 56.0% and is now trading at $3.90. View the best growth stocks for 2024 here. How were Arbutus Biopharma's earnings last quarter? Arbutus Biopharma Co. (NASDAQ:ABUS) issued its earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). The biopharmaceutical company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $2.16 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 62.68% and a negative net margin of 572.81%. What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO? 6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Arbutus Biopharma's major shareholders? Arbutus Biopharma's top institutional shareholders include Bank of New York Mellon Corp (0.26%), Clear Harbor Asset Management LLC (0.05%), Premier Path Wealth Partners LLC (0.02%) and Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of Arbutus Biopharma? Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arbutus Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH) and Inovio Pharmaceuticals (INO). This page (NASDAQ:ABUS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
